Evidence map›Paper›PMID 42745798›Full record

ArticleFrontiers in oncology2026

ZEB1 directly activates IL-6 to promote triple-negative breast cancer stemness in an epigenetically constrained context.

Weiyue Zhang, Yifan Zhou, Wei Ma, Huimin Jiang

Abstract read
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Weiyue ZhangSchool of Biological Science and Medical Engineering, Beihang University, Beijing, China.
Yifan ZhouBeijing Institute of Brain Disorders, Laboratory of Brain Disorders, Ministry of Science and Technology, Collaborative Innovation Center for Brain Disorders, Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, Capital Medical University, Beijing, China.
Wei MaBeijing Institute of Brain Disorders, Laboratory of Brain Disorders, Ministry of Science and Technology, Collaborative Innovation Center for Brain Disorders, Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, Capital Medical University, Beijing, China.
Huimin JiangBeijing Institute of Brain Disorders, Laboratory of Brain Disorders, Ministry of Science and Technology, Collaborative Innovation Center for Brain Disorders, Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, Capital Medical University, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ZEB1 is a key driver of breast cancer pathogenesis and therapy resistance, largely through its ability to promote cancer stem cells (CSCs). Although tumor-secreted cytokines such as IL-6 are known to support tumor progression, how their expression is regulated by upstream transcriptional factors such as ZEB1 remains incompletely understood. Here, we identify IL-6 as a direct transcriptional target of ZEB1 and reveal an epigenetic dimension associated with this regulation. Mechanistically, ZEB1 binds to specific E2-box elements within the IL-6 promoter and activates its transcription. The IL-6 promoter exhibits local DNA methylation, and ZEB1-dependent IL-6 expression was further enhanced by DNA methyltransferase and histone deacetylase inhibitors, suggesting that the local epigenetic context constrains IL-6 transcription. ZEB1 overexpression was also accompanied by enrichment of the active histone marks H3K27ac and H3K4me3 at the IL-6 promoter, consistent with a more transcriptionally permissive local chromatin state. Functionally, the ZEB1-induced IL-6 expression enhanced CSC-associated properties

Indexed as

cancer stem cellsepigenetic regulationIL-6triple-negative breast cancerZEB1

Identifiers

PMID42745798
PMCPMC13574650

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.